Devacell, Inc.

United States of America

Back to Profile

1-9 of 9 for Devacell, Inc. Sort by
Query
Aggregations
IP Type
        Patent 8
        Trademark 1
Jurisdiction
        United States 5
        World 4
Date
2024 1
2023 2
2022 2
2021 1
Before 2020 3
IPC Class
A61K 35/768 - Oncolytic viruses not provided for in groups 3
A61K 9/51 - Nanocapsules 3
C12N 15/86 - Viral vectors 3
A61K 35/761 - Adenovirus 2
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof 2
See more
Status
Pending 3
Registered / In Force 6

1.

RECOMBINANT ONCOLYTIC VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS

      
Application Number 18254138
Status Pending
Filing Date 2021-11-23
First Publication Date 2024-01-25
Owner DEVACELL, INC. (USA)
Inventor Ortac, Inanc

Abstract

Provided herein are recombinant viruses and artificially coated delivery systems, and methods of use.

IPC Classes  ?

  • C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
  • A61P 35/00 - Antineoplastic agents

2.

RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS

      
Application Number 18030956
Status Pending
Filing Date 2021-10-07
First Publication Date 2023-11-16
Owner DEVACELL, INC. (USA)
Inventor Ortac, Inanc

Abstract

Provided herein are recombinant viruses and artificially coated delivery systems, and methods of use.

IPC Classes  ?

  • A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
  • C12N 15/86 - Viral vectors
  • C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
  • A61K 35/768 - Oncolytic viruses not provided for in groups
  • A61P 31/14 - Antivirals for RNA viruses

3.

RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS

      
Application Number 18007902
Status Pending
Filing Date 2021-06-04
First Publication Date 2023-08-31
Owner DEVACELL, INC. (USA)
Inventor Ortac, Inanc

Abstract

Provided herein are recombinant viruses and artificially coated delivery systems, and methods of use.

IPC Classes  ?

4.

RECOMBINANT ONCOLYTIC VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS

      
Application Number US2021060669
Publication Number 2022/109503
Status In Force
Filing Date 2021-11-23
Publication Date 2022-05-27
Owner DEVACELL, INC. (USA)
Inventor Ortac, Inanc

Abstract

Provided herein are recombinant viruses and artificially coated delivery systems, and methods of use.

IPC Classes  ?

5.

RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS

      
Application Number US2021054068
Publication Number 2022/076756
Status In Force
Filing Date 2021-10-07
Publication Date 2022-04-14
Owner DEVACELL, INC. (USA)
Inventor Ortac, Inanc

Abstract

Provided herein are recombinant viruses and artificially coated delivery systems, and methods of use.

IPC Classes  ?

6.

RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS

      
Application Number US2021036021
Publication Number 2021/248080
Status In Force
Filing Date 2021-06-04
Publication Date 2021-12-09
Owner DEVACELL, INC. (USA)
Inventor Ortac, Inanc

Abstract

Provided herein are recombinant viruses and artificially coated delivery systems, and methods of use.

IPC Classes  ?

7.

ONCOAT

      
Serial Number 87734662
Status Registered
Filing Date 2017-12-26
Registration Date 2020-07-07
Owner DevaCell, Inc. ()
NICE Classes  ? 42 - Scientific, technological and industrial services, research and design

Goods & Services

Medical research and development services, namely, developing cancer treatments by applying coatings to oncolytic viruses with a nano-encapsulation of organic and inorganic materials as a service to companies

8.

Enzyme-encapsulated nanoparticle platform

      
Application Number 15022551
Grant Number 10300152
Status In Force
Filing Date 2014-09-17
First Publication Date 2016-08-25
Grant Date 2019-05-28
Owner
  • The Regents of the University of California (USA)
  • Devacell, Inc. (USA)
Inventor
  • Ortac, Inanc
  • Esener, Sadik C.
  • Yayla, Ibrahim Gokce
  • Messmer, Bradley

Abstract

Disclosed are methods, systems, and devices for implementing nanoparticles to encapsulate biomolecules such as enzymes. In one aspect, a nanoparticle device includes a shell structure including an internal layer structured to enclose a hollow interior region and include one or more holes penetrating through the internal layer, and an external layer formed of a porous material around the internal layer; and an enzyme contained within the interior region of the shell structure, the enzyme having entered the shell structure through the one or more holes and incapable of passing through the external layer, in which the pores are of a size that prevents the enzyme to pass through the pores while permitting substances smaller than the pore size to pass through the pores.

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes Identification of persons
  • A61K 9/51 - Nanocapsules
  • C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
  • C12Q 1/30 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase involving catalase
  • C12Q 1/54 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving glucose or galactose
  • A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
  • A61K 38/50 - Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
  • A61K 49/00 - Preparations for testing in vivo
  • A61K 49/22 - Echographic preparationsUltrasound imaging preparations
  • A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters

9.

ENZYME-ENCAPSULATED NANOPARTICLE PLATFORM

      
Application Number US2014056179
Publication Number 2015/042204
Status In Force
Filing Date 2014-09-17
Publication Date 2015-03-26
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • DEVACELL, INC. (USA)
Inventor
  • Ortac, Inanc
  • Esener, Sadik, C.
  • Yayla, Ibrahim, Gokce
  • Messmer, Bradley

Abstract

Disclosed are methods, systems, and devices for implementing nanoparticles to encapsulate biomolecules such as enzymes. In one aspect, a nanoparticle device includes a shell structure including an internal layer structured to enclose a hollow interior region and include one or more holes penetrating through the internal layer, and an external layer formed of a porous material around the internal layer; and an enzyme contained within the interior region of the shell structure, the enzyme having entered the shell structure through the one or more holes and incapable of passing through the external layer, in which the pores are of a size that prevents the enzyme to pass through the pores while permitting substances smaller than the pore size to pass through the pores.

IPC Classes  ?